Sustained response of Hepatitis B e Antigen-Negative patients 3 years after treatment with Peginterferon Alfa-2a

Simple item page
dc.contributor.authorYurdaydın, Cihan
dc.contributor.authorMarcellin, Patrick
dc.contributor.authorBonino, Ferruccio
dc.contributor.authorLau, George
dc.contributor.authorFarci, Patrizia
dc.contributor.authorPiratvisuth, Teerha
dc.contributor.authorJin, Rui
dc.contributor.authorLu, Zhi-Meng
dc.contributor.authorWu, Jian
dc.contributor.authorPopescu, Matei
dc.contributor.authorHadziyannis, Stephanos
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.tr_TR
dc.contributor.scopusid7003706434tr_TR
dc.date.accessioned2021-10-21T09:22:07Z
dc.date.available2021-10-21T09:22:07Z
dc.date.issued2009-06
dc.description.abstractBackground & Aims: Patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treated with peginterferon alfa-2a with or without lamivudine achieve significantly higher 6-month posttreatment rates of response compared with those treated with lamivudine alone. The durability of <= 3-year posttreatment response was investigated in this study. Methods: Patients received peginterferon alfa-2a only (180 p,g once weekly; n = 177), in combination with lamivudine (100 mg daily; n = 179) or lamivudine alone (n = 181) for 48 weeks. A total of 315 patients (116, 114, and 85, respectively) participated in this posttreatment observational study. Results: Three years after treatment, the percentage of patients with normal alanine aminotransferase (ATL) was higher for patients treated with peginterferon alfa-2a (31%) than with lamivudine (18%; P = 0.032). Similarly, 28% of patients treated with peginterferon had hepatitis B virus (HBV) DNA levels 10,000 copies/mL versus 15% of patients treated with lamivudine (P = .039). Peginterferon alfa-2a treatment and high baseline ALT level were independent baseline predictors of long-term virologic response (P = .040 and P = .01, respectively). Of the patients who had been treated with a peginterferon alfa-2a-containing regimen, 8.7% cleared hepatitis B surface antigen (HBsAg; 44% of those with undetectable HBV at 3-year posttreatment follow-up) compared with none treated with lamivudine alone. Conclusions: Biochemical and virologic responses were sustained for 53 years in approximately 25% of patients given a 48-week course of peginterferon alfa-2a, with or without lamivudine. The increased rate of HBsAg clearance in patients with HBeAg-negative chronic hepatitis B supports the use of peginterferon alfa-2a as a first-line treatment.en_US
dc.description.sponsorshipHoffmann-La Rocheen_US
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Allergy & Infectious Diseases (NIAID) ( ZIAAI000999)en_US
dc.identifier.citationMarcellin, P. vd. (2009) "Sustained response of Hepatitis B e Antigen-Negative patients 3 years after treatment with Peginterferon Alfa-2a". Gastroenterology, 136(7), 2169-2179.en_US
dc.identifier.endpage2179tr_TR
dc.identifier.issn0016-5085
dc.identifier.issue7tr_TR
dc.identifier.pubmed19303414tr_TR
dc.identifier.scopus2-s2.0-66449121130tr_TR
dc.identifier.startpage2169tr_TR
dc.identifier.urihttps://doi.org/10.1053/j.gastro.2009.03.006
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S0016508509003771
dc.identifier.urihttp://hdl.handle.net/11452/22425
dc.identifier.volume136tr_TR
dc.identifier.wos000266659100020tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWB Saunders Co-Elsevieren_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalGastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTerm-follow-upen_US
dc.subjectAdefovir dipivoxilen_US
dc.subjectUntreated patientsen_US
dc.subjectSerum hbsagen_US
dc.subjectHbeagen_US
dc.subjectInterferonen_US
dc.subjectLamivudineen_US
dc.subjectTherapyen_US
dc.subjectCearanceen_US
dc.subjectDiseaseen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subject.emtreeAlanine aminotransferaseen_US
dc.subject.emtreeHepatitis B(e) antigenen_US
dc.subject.emtreeLamivudineen_US
dc.subject.emtreePeginterferon alpha2aen_US
dc.subject.emtreeVirus DNAen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAlanine aminotransferase blood levelen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug dose regimenen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHepatitis Ben_US
dc.subject.emtreeHepatitis B virusen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeVirologyen_US
dc.subject.scopusHepatitis B E Antigen; Entecavir; Telbivudineen_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.titleSustained response of Hepatitis B e Antigen-Negative patients 3 years after treatment with Peginterferon Alfa-2aen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus